Orthofix Medical Inc. $OFIX is Juniper Investment Company LLC's 4th Largest Position

Key Points

• Juniper Investment Company LLC increased its stake in Orthofix Medical Inc. by 10.3%, making it the firm's 4th largest position at 2,137,374 shares.
• The company reported a loss of ($0.36) earnings per share for the last quarter, significantly missing analysts' expectations of $0.04.
• Despite the earnings miss, the stock has received a consensus rating of "Buy" from analysts, with an average price target of $21.50.

Juniper Investment Company LLC increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 10.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,137,374 shares of the medical device company's stock after purchasing an additional 200,125 shares during the period. Orthofix Medical makes up 15.7% of Juniper Investment Company LLC's holdings, making the stock its 4th largest position. Juniper Investment Company LLC owned approximately 5.48% of Orthofix Medical worth $34,861,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Engine Capital Management LP boosted its stake in Orthofix Medical by 8.4% in the 1st quarter. Engine Capital Management LP now owns 3,741,390 shares of the medical device company's stock worth $61,022,000 after purchasing an additional 290,646 shares during the period. AQR Capital Management LLC boosted its stake in shares of Orthofix Medical by 67.7% during the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company's stock worth $333,000 after buying an additional 8,241 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Orthofix Medical during the 1st quarter worth about $548,000. Cubist Systematic Strategies LLC boosted its stake in shares of Orthofix Medical by 161.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 78,220 shares of the medical device company's stock worth $1,276,000 after buying an additional 48,353 shares during the last quarter. Finally, Trexquant Investment LP boosted its stake in shares of Orthofix Medical by 8.7% during the 1st quarter. Trexquant Investment LP now owns 60,536 shares of the medical device company's stock worth $987,000 after buying an additional 4,856 shares during the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Orthofix Medical

In related news, insider Aviva Mcpherron sold 3,728 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total value of $39,181.28. Following the transaction, the insider owned 46,322 shares in the company, valued at $486,844.22. The trade was a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on OFIX shares. Barrington Research upgraded shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 price objective for the company in a research note on Monday, June 23rd. Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $21.50.

Orthofix Medical Stock Performance

Shares of OFIX traded down $0.09 during mid-day trading on Tuesday, hitting $14.61. 305,375 shares of the company's stock were exchanged, compared to its average volume of 337,434. Orthofix Medical Inc. has a 52 week low of $10.24 and a 52 week high of $20.73. The stock's 50-day simple moving average is $12.62 and its 200-day simple moving average is $13.29. The firm has a market cap of $576.95 million, a price-to-earnings ratio of -4.61 and a beta of 0.86. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.40). Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%.The business had revenue of $203.12 million for the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.